ERα inhibitors (like Tamoxifen and Raloxifene) and HER2 inhibitors (like Trastuzumab and Pertuzumab) are administered to Luminal A/B and HER2+ diagnosed breast cancer patients, respectively [44,45]. The gene discussed is ERBB2; the disease is breast carcinoma.